Inclusion Criteria:  Documented diagnosis of intermediate-2/ high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% bone marrow blasts and multi-lineage dysplasia Initiated azacitidine (AZA) treatment per approved China Product Label after April 2017  Exclusion Criteria:  Contraindicated for the use of AZA according to China Product Label Simultaneously participating in a treatment intervention study  Other protocol-defined inclusion/exclusion criteria apply.